A Randomised, Double Blind, Placebo Controlled, Single Centre, Three-Part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of ONO-2808 in Healthy Subjects
Latest Information Update: 03 Jan 2022
At a glance
- Drugs ONO 2808 (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions; First in man
- Sponsors Ono Pharmaceutical
- 10 Dec 2021 Status changed from recruiting to completed.
- 09 Oct 2020 New trial record